Motixafortide (Aphexda)
Jump to navigation
Jump to search
Mechanism of action
cyclic-peptide CXCR4 inhibitor
History of changes in FDA indication
- 2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. (Based on GENESIS)
Also known as
- Code names: BKT-140, BL-8040, TF-14016
- Brand name: Aphexda